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INTRODUCTION
High-dose intravenous immunoglobulin (IVIG) has been
used safely in various autoimmune disorders such as Kawasa-
ki syndrome, hemolytic anemia, neuroimmunological disor-
ders, and idiopathic thrombocytopenic purpura (ITP). The
therapeutic indications for the use of IVIG have been broad-
ened to include various diseases during the last few decades
(1-3). Serious adverse reactions of IVIG are rare, including
anaphylactic reactions, especially in patients with selective
IgA deficiency, renal tubular necrosis and aseptic meningi-
tis. In general, IVIG has been considered a safe medication,
with manageable adverse events such as fever, chills, myalgia,
and headache, occurring in no more than 10% of the patients
(1, 4-7).
Since the thromboembolic complications associated with
IVIG treatment was first reported by Woodruff et al. (8) in
1986, IVIG-associated thrombotic complications have been
steadily reported, and the incidence has been estimated to be
between 3% and 5% (1, 2). In Korea, a case of cerebral infarc-
tion following IVIG therapy in a patient with Guillain-Barre
syndrome has been reported (9).
In this report, we describe a case of IVIG-induced deep
vein thrombosis with pulmonary thromboembolism in an
ITP patient without underlying cardiovascular risk factors. 
CASE REPORT
A 56-yr-old woman presented with petechiae and bruises,
which had developed six months before. She had no previ-
ous medical history or family history of bleeding or throm-
botic tendency. She denied use of any medication, such as
oral contraceptives, herbs, aspirin, nonsteroidal anti-inflam-
matory agents, or antibiotics. On physical examination, she
had petechiae on palate and bruise on her upper and lower
extremities. Calf swelling and splenomegaly were not notic-
ed. Her initial platelet count was 3,000/ L, hemoglobin
12.6 g/dL, and white blood cell count 7,720/ L. Antipla-
telet antibody was negative. Peripheral blood smear showed
markedly decreased platelet in number. Bone marrow aspi-
rate and biopsy showed relatively hypocellular marrow for
her age with normal maturation (cellularity 25%), and mega-
karyocytes were adequate in number with normal matura-
tion. After the diagnosis of ITP, high-dose prednisolone (1
mg/kg) was administered for 2 months, to which the patient
was refractory. For acute management of gum bleeding at
platelet count 10,000/ L, she received IVIG at a dose of 400
mg/kg/day for five days with no immediate acute toxicities
during infusion. Three days after the administration of IVIG,
the patient developed painful edema in her left leg. She did
not complain of respiratory or cardiac symptoms such as dys-
pnea or tachypnea. On physical examination, pitting edema
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A Case of Deep Vein Thrombosis and Pulmonary Thromboembolism 
after Intravenous Immunoglobulin Therapy 
Although high-dose intravenous immunoglobulin (IVIG) is generally considered a
safe medication for various immune-mediated diseases, thrombotic events have
been reported as a complication of the therapy. We report a case who developed
thrombotic complications after receiving IVIG. A 56-yr-old woman with idiopathic
thrombocytopenic purpura received IVIG at a dose of 400 mg/kg/day for five days.
Three days after the administration of IVIG, the patient developed painful edema
in the left leg. Lower extremity doppler ultrasound revealed deep vein thrombosis
in the left leg. Chest computed tomography (CT) scan demonstrated a filling defect
indicating thromboembolism of the right pulmonary artery. After three weeks of eno-
xaparin therapy, her symptoms and pulmonary embolism on CT improved. This
case suggests clinicians should be cautious in the development of thromboem-
bolism by administration of IVIG, especially in patients with thrombophilia.
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of grade III was noticed in her left lower leg with weakly
palpated pulse at left dorsalis pedis artery. Her hemoglobin
level was 11.4 g/dL, hematocrit 36.4%, white blood cell
count 2,210/ L, and platelets 14,000/ L. VDRL and FANA
were all negative. Lupus anticoagulant was 35.0 sec and anti-
cardiolipin antibodies, IgM and IgG, were negative. Anti-
thrombin III activity, protein C and protein S activity, and
homocysteine were within normal limits. An electrocardio-
gram showed a normal sinus rhythm at 65 beats per minute
with a normal axis and intervals. Her chest radiograph was
normal. Transthoracic echocardiogram showed normal left
ventricular cavity size and systolic function, diastolic dys-
function of grade I, and right ventricular systolic pressure of
32 mmHg. Extremity doppler ultrasound revealed diffuse
thrombosis from the left proximal femoral vein to the pop-
liteal vein (Fig. 1). Chest CT scan revealed a filling defect in
the right interlobar pulmonary artery, which was indicative
of thromboembolism (Fig. 2). She was immediately treated
with subcutaneous enoxaparin at a dose of 60 mg twice a
day. After three weeks of enoxaparin therapy, her follow-up
Fig. 1. Lower extremity Doppler ultrasound revealed thrombus in the left femoral vein.
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Fig. 2. Chest computed tomography scan revealed a filling defect in the right interlobar pulmonary artery (arrow), indicating pulmonary
thromboembolism.
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chest CT scan revealed a complete disappearance of embolism
in the right pulmonary artery (Fig. 3). Pitting edema in the
left lower leg was completely resolved, and platelet count
was normalized following high-dose steroid therapy. Because
her platelet count was persistently decreased despite high-
dose steroid therapy, she underwent splenectomy. After sple-
nectomy, her platelet count was stabilized with a range of
45,000-50,000/ L while on prednisolone and danazol and
has achieved complete remission. She is currently on war-
farin for deep vein thrombosis. 
DISCUSSION
ITP is one of the immunologic thrombocytopenic purpu-
ra characterized by the development of autoantibodies react-
ing on platelet glycoproteins, which are then destroyed by
phagocytosis primarily in spleen. 
In the treatment of ITP, IVIG is used for patients with
active bleeding or for whom major surgery is necessary (10,
11). High-dose IVIG was first used for treatment of child-
hood ITP by Imbach et al. (12) in 1981. The six indications
approved for the IVIG product in Canadian Consensus guide-
line (1999) (13) include immune deficiency, idiopathic thro-
mbocytopenic purpura, hypogammaglobulinemia, pediatric
Human Immunodeficiency Virus (HIV) infection, bone mar-
row transplantation, and B cell chronic lymphocytic leukemia.
However, the clinical use of IVIG is far from being restricted
to the approved indications and off-label uses such as chron-
ic inflammatory demyelinating polyneuropathy and Guil-
lain-Barre syndrome are common (13, 14). In general, IVIG
has been considered a safe medication, with minor adverse
reactions such as fatigue, fever, headache, nausea, and myal-
gias, occurring in no more than 10% of patients (1, 4-7).
With the wider use of IVIG, the reported rate of side effects
has increased, some of them being potentially fatal (1, 8).
The first report of thromboembolic events associated with
IVIG therapy by Woodruff et al. (8). described four older
patients with ITP who developed myocardial infarction and
cerebrovascular accident after IVIG therapy, resulting in death
in three of them. Paran et al. (14) described that 65 cases of
IVIG-associated thrombosis had been reported in 33 articles
published from 1966 to 2004 and 34 of these cases were
reported in 2003. In the report, 51 cases had arterial throm-
bosis, including stroke, myocardial infarction, and limb is-
chemia. Thirteen cases had venous thrombosis, including
deep vein thrombosis or pulmonary embolism, central reti-
nal vein thrombosis, and sinus vein thrombosis. Two of the
reported patients had both an arterial and a venous thrombot-
ic event (14). Thromboembolic complications occurred within
two weeks after IVIG therapy had begun, and the 63% of
them occurred within 24 hr of the infusion (1, 2, 8, 14-16).
Although the pathogenesis of thrombosis secondary to IVIG
is not completely understood, several mechanisms have been
proposed. One plausible mechanism for IVIG-related throm-
bosis is the increase in blood viscosity by IVIG. High-dose
IVIG increases blood viscosity from normal (1.2-1.7 cp) by
0.5 to 0.7 cp, thus causing a hypercoagulable state (2, 4, 9,
16). Previous studies reported that serum viscosity increased
up to 2.9 cp immediately, following infusion of IVIG and
declined gradually over the next month (14, 17). In particu-
lar, IgG has been postulated to increase viscosity through
molecular interactions between proteins (2, 16, 17). The vis-
cous effect of IVIG is dose-dependent and increases the suscep-
Fig. 3. The filling defect in the right interlobar pulmonary artery disappeared after 3 weeks of enoxaparin therapy.
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tibility to thromboembolism in predisposed patients such
as elderly patients and those with cardiovascular or cerebro-
vascular disease and atherosclerosis (1, 5, 16). If such patients
are planned to receive IVIG, pretreatment screening with
lower extremity ultrasound for subclinical clots, very slow
infusion rate (not exceeding 200 mL/hr or 0.08 mL/kg/min)
and monitoring of serum viscosity are recommended (1, 4).
In addition, IVIG induces platelet activation, increased fib-
rinogen levels and activation of the serum complement,
which may further predispose patients to thrombosis and
ischemia. Some IVIG preparations have increased concen-
trations of factor XI, which may potentially trigger intrinsic
coagulation pathway activation and thrombin formation (5,
16). Besides, IVIG may induce localized production of vaso-
constrictive cytokines and arterial vasospasm leading to th-
rombotic events (5).
Irrespective of IVIG therapy, thromboembolic complica-
tions, such as portal vein thrombosis, pulmonary embolism,
and deep vein thrombosis may occur following splenectomy
for hematologic diseases (18, 19). However, in our case, the
patient experienced thromboembolic complications imme-
diately following IVIG before splenectomy, which excludes
this possibility.
Although a direct underlying mechanism responsible for
IVIG-induced thrombotic events needs to be clarified, IVIG
should be given with precaution in patients with vascular
risk factors such as advanced age, history of cerebrovascular
or cardiovascular disease, hypertension, or hypercoagulable
and hyperviscosity conditions.
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